Hims & Hers Health, Inc. (HIMS) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$26.33
Price Target
$29.67
Target Range
$12.50 — $60.00
Analyst Rating
Hold
Forward P/E52.8x
Trailing P/E51.6x
Forward PEG—
Implied Growth-3.7%
Median Target$26.50
Analyst Spread160.1%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$13
-52.5%
Consensus
$30
+12.7%
Bull Case
$60
+127.9%
HIMS Price Target Analysis
Updated May 6, 2026As of May 6, 2026, Hims & Hers Health, Inc. (HIMS) has a Wall Street consensus price target of $29.67, based on estimates from 19 covering analysts. With the stock currently trading at $26.33, this represents a potential upside of +12.7%. The company has a market capitalization of $6.80B.
Analyst price targets range from a low of $12.50 to a high of $60.00, representing a 160% spread in expectations. The median target of $26.50 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Hold, with 6 analysts rating the stock as a Buy or Strong Buy,13 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, HIMS trades at a trailing P/E of 51.6x and forward P/E of 52.8x. Analysts expect EPS to grow -3.7% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+39.5%
Avg Forward P/E24.3x
Peers with Coverage9 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 TDOCTeladoc Health, Inc. | $1.2B | $6.66 | $7.58 | +13.8% | Hold | — | 42 |
 DOCSDoximity, Inc. | $5.2B | $25.77 | $42.79 | +66.0% | Buy | 16.7x | 22 |
 OPRXOptimizeRx Corporation | $124M | $6.63 | $17.00 | +156.4% | Buy | 7.0x | 15 |
 WELLWelltower Inc. | $150.1B | $214.30 | $226.50 | +5.7% | Buy | 78.9x | 34 |
 NVONovo Nordisk A/S | $151.4B | $44.89 | $47.00 | +4.7% | Buy | 2.1x | 39 |
 LLYEli Lilly and Company | $933.7B | $988.19 | $1258.47 | +27.4% | Buy | 28.6x | 45 |
 AMWLAmerican Well Corporation | $107M | $6.41 | — | — | — | — | — |
 TALKTalkspace, Inc. | $871M | $5.20 | $5.25 | +1.0% | Hold | 38.3x | 10 |
 GDRXGoodRx Holdings, Inc. | $709M | $2.56 | $3.19 | +24.6% | Hold | 8.1x | 24 |
 HCATHealth Catalyst, Inc. | $114M | $1.60 | $2.50 | +56.3% | Buy | 14.2x | 22 |
Upside Potential Comparison
OPRXDOCSHCATLLYGDRXTDOCWELLNVOSee HIMS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs HIMS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare HIMS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonHIMS — Frequently Asked Questions
Quick answers to the most common questions about buying HIMS stock.
What is the HIMS stock price target for 2026?
Hims & Hers Health, Inc. (HIMS) has a consensus 12-month price target of $29.67, implying 12.7% upside from $26.33. The 19 analysts covering HIMS see moderate appreciation potential.
Is HIMS a buy, sell, or hold?
HIMS has a consensus rating of "Hold" based on 19 Wall Street analysts. The rating breakdown is mixed, with 13 Hold ratings making up the largest segment. The consensus 12-month price target of $29.67 implies 12.7% upside from current levels.
Is HIMS stock overvalued or undervalued?
At a forward P/E of 52.8397x, HIMS trades at a premium valuation. The consensus price target of $29.67 (12.7% upside) suggests analysts still see growth justifying the multiple.
How high can HIMS stock go?
The most bullish Wall Street analyst has a price target of $60 for HIMS, while the most conservative target is $12.5. The consensus of $29.67 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover HIMS stock?
HIMS is well covered by analysts, with 19 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 13 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the HIMS stock forecast?
The 12-month HIMS stock forecast based on 19 Wall Street analysts shows a consensus price target of $29.67, with estimates ranging from $12.5 (bear case) to $60 (bull case). The median consensus rating is "Hold".
What is HIMS's forward P/E ratio?
HIMS trades at a forward P/E ratio of 52.8x based on next-twelve-months earnings estimates compared to a trailing P/E of 51.6x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy HIMS stock?
Wall Street analysts are optimistic on HIMS, with a "Hold" consensus rating and $29.67 price target (12.7% upside). 6 of 19 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do HIMS price targets vary so much?
HIMS analyst price targets range from $12.5 to $60, a 160% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $29.67 consensus represents the middle ground.